144 related articles for article (PubMed ID: 27567007)
1. Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks.
Morris MK; Clarke DC; Osimiri LC; Lauffenburger DA
CPT Pharmacometrics Syst Pharmacol; 2016 Oct; 5(10):544-553. PubMed ID: 27567007
[TBL] [Abstract][Full Text] [Related]
2. Querying quantitative logic models (Q2LM) to study intracellular signaling networks and cell-cytokine interactions.
Morris MK; Shriver Z; Sasisekharan R; Lauffenburger DA
Biotechnol J; 2012 Mar; 7(3):374-86. PubMed ID: 22125256
[TBL] [Abstract][Full Text] [Related]
3. Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli.
Morris MK; Saez-Rodriguez J; Clarke DC; Sorger PK; Lauffenburger DA
PLoS Comput Biol; 2011 Mar; 7(3):e1001099. PubMed ID: 21408212
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury.
Liao PH; Hsu HH; Chen TS; Chen MC; Day CH; Tu CC; Lin YM; Tsai FJ; Kuo WW; Huang CY
Oncogene; 2017 Apr; 36(14):1978-1990. PubMed ID: 27748761
[TBL] [Abstract][Full Text] [Related]
5. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
[TBL] [Abstract][Full Text] [Related]
6. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
7. Construction of cell type-specific logic models of signaling networks using CellNOpt.
Morris MK; Melas I; Saez-Rodriguez J
Methods Mol Biol; 2013; 930():179-214. PubMed ID: 23086842
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma.
Liu T; Ma H; Shi W; Duan J; Wang Y; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Int J Oncol; 2017 Aug; 51(2):555-562. PubMed ID: 28714512
[TBL] [Abstract][Full Text] [Related]
9. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
[TBL] [Abstract][Full Text] [Related]
12. SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Zhao P; Chen L; Li LH; Wei ZF; Tong B; Jia YG; Kong LY; Xia YF; Dai Y
BMC Cancer; 2014 Dec; 14():987. PubMed ID: 25527123
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the Tumor Metastatic Microenvironment and Multiple Signal Pathways by Prunella vulgaris in Human Hepatocellular Carcinoma.
Su YC; Lin IH; Siao YM; Liu CJ; Yeh CC
Am J Chin Med; 2016; 44(4):835-49. PubMed ID: 27222069
[TBL] [Abstract][Full Text] [Related]
15. SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma.
Zhang Z; Yan Z; Yuan Z; Sun Y; He H; Mai C
Tumour Biol; 2015 Mar; 36(3):1503-9. PubMed ID: 25537088
[TBL] [Abstract][Full Text] [Related]
16. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
17. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
Lin D; Wu J
World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
[TBL] [Abstract][Full Text] [Related]
19. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
20. Houttuynia cordata Thunb Promotes Activation of HIF-1A-FOXO3 and MEF2A Pathways to Induce Apoptosis in Human HepG2 Hepatocellular Carcinoma Cells.
Kim JM; Hwang IH; Jang IS; Kim M; Bang IS; Park SJ; Chung YJ; Joo JC; Lee MG
Integr Cancer Ther; 2017 Sep; 16(3):360-372. PubMed ID: 27698266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
